NuCana Q2 2026
NuCana (NASDAQ:NCNA) will report on Q2 2026.
Stocks · News reference
NuCana Has Been Granted European Patent Number EP3683225 Titled "NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS"
https://register.epo.org/application?number=EP19181028
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading